Julia Leigh of Shaw and Partners highlighted BHP as a preferred mining investment despite growth challenges, emphasizing diversification into minerals like lithium and uranium, while also noting CSL’s strong outlook and the Australian healthcare sector’s undervaluation attracting foreign interest. The Australian market shows robust earnings growth driven by healthcare, energy, and materials, though investors remain cautious amid sectoral variations and evolving market conditions.
In the discussion with Julia Leigh, investment director at Shaw and Partners Asset Management, the focus was initially on BHP’s recent performance. Despite strong operational results and rising copper prices, there are concerns about BHP’s future growth prospects. While the company currently generates significant cash flow and offers attractive dividends, the challenge lies in identifying new growth avenues, especially as iron ore demand declines and copper mine development is a lengthy process. Mergers and acquisitions (M&A) may be the primary strategy for expansion, but the market remains cautious about the sustainability of copper prices due to potential substitution effects and tariff uncertainties.
When comparing miners, Julia highlighted BHP as the preferred exposure in their portfolios, with limited investment in Fortescue Metals despite its recent diversification into copper. She also emphasized the importance of diversifying into other minerals such as lithium and uranium, noting the recent rebound in lithium prices after a period of decline. This diversification strategy aims to capture growth in sectors beyond copper, which has already experienced a significant run-up in value.
The conversation then shifted to CSL, a major healthcare stock that recently experienced a notable price increase despite reporting a substantial loss. Julia explained that the market’s positive reaction was driven by CSL’s optimistic outlook, forecasting 5% growth, which exceeded previous expectations of no growth. She mentioned that CSL remains overweight in their portfolio due to its attractive valuation and the stabilization of underlying business areas, despite the volatility seen in the healthcare sector overall.
Julia also discussed the broader Australian healthcare sector, noting its relative undervaluation compared to global markets. This has attracted offshore interest and M&A activity, with foreign companies seeking acquisitions in Australia. The sector’s value proposition has benefited from a rotation of investment away from sectors like energy and into healthcare, which is seen as a more stable and promising area amid market fluctuations.
Finally, Julia provided an overview of the Australian earnings season, which began with high expectations of 12% growth—the highest in four years. Although momentum has slightly moderated to 11.7%, this remains robust. Earnings growth has varied across sectors, with consumer discretionary facing challenges, while healthcare, energy, and materials have performed well. Overall, the Australian market has shown resilience, but investors are closely watching for further developments as earnings reports continue to unfold.